Works matching DE "ADUCANUMAB"

Results: 139

New drugs for Alzheimer’s disease: Aducanumab or Donanemab?

Published in:

Physiology & Pharmacology, 2024, v. 28, n. 3, p. 219, doi. 10.61186/phypha.28.3.219

By:

Joodaki, Mehran;
Shirazi, Mona Merati;
Hosseini, Nasrin

Publication type:

Article

Immunothérapie passive dans la maladie d'Alzheimer : état des lieux et applicabilité en population gériatrique.

Published in:

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 2023, v. 21, n. 2, p. 233, doi. 10.1684/pnv.2023.1099

By:

Delrieu, Julien;
Ousset, Pierre Jean

Publication type:

Article

Actualités thérapeutiques dans la maladie d'Alzheimer : bientôt un traitement de fond ?

Published in:

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 2022, v. 20, n. 2, p. 256, doi. 10.1684/pnv.2022.1042

By:

Villain, Nicolas

Publication type:

Article

The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology.

Published in:

Neurosciences, 2023, v. 28, n. 2, p. 77, doi. 10.17712/nsj.2023.2.20220133

By:

Tayeb, Haythum O.;
Khallaf, Roaa A.;
Muayqil, Taim A.;
Alkeridy, Walid A.;
Alibrahim, Fawwaz S.;
Alfaify, Omar A.;
Qadi, Najeeb;
Tarazi, Frank I.

Publication type:

Article

Alzheimer's Disease Treatment: The Search for a Breakthrough.

Published in:

Medicina (1010660X), 2023, v. 59, n. 6, p. 1084, doi. 10.3390/medicina59061084

By:

Reiss, Allison B.;
Muhieddine, Dalia;
Jacob, Berlin;
Mesbah, Michael;
Pinkhasov, Aaron;
Gomolin, Irving H.;
Stecker, Mark M.;
Wisniewski, Thomas;
De Leon, Joshua

Publication type:

Article

Comment on NATSEM's report on the economic and societal cost of Alzheimer disease in Australia.

Published in:: Medical Journal of Australia, 2022, v. 216, n. 10, p. 540, doi. 10.5694/mja2.51521
Publication type:: Article

Does the FDA‐approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?

Published in:

Medical Journal of Australia, 2022, v. 216, n. 4, p. 172, doi. 10.5694/mja2.51408

By:

Gleason, Andrew;
Ayton, Scott;
Bush, Ashley I

Publication type:

Article

Journal Club.

Published in:

Zeitschrift für Gerontologie und Geriatrie, 2024, v. 57, n. 3, p. 244, doi. 10.1007/s00391-024-02288-2

By:

Dovjak, Peter

Publication type:

Article

From 1901 to 2022, how far are we from truly understanding the pathogenesis of age-related dementia?

Published in:

GeroScience, 2022, v. 44, n. 3, p. 1879, doi. 10.1007/s11357-022-00591-7

By:

Fang, Xing;
Zhang, Jin;
Roman, Richard J.;
Fan, Fan

Publication type:

Article

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 1, p. 62, doi. 10.1002/psp4.12876

By:

Ramakrishnan, Vidya;
Friedrich, Christina;
Witt, Colleen;
Sheehan, Robert;
Pryor, Meghan;
Atwal, Jasvinder K.;
Wildsmith, Kristin;
Kudrycki, Katherine;
Lee, Seung‐Hye;
Mazer, Norman;
Hofmann, Carsten;
Fuji, Reina N.;
Jin, Jin Y.;
Ramanujan, Saroja;
Dolton, Michael;
Quartino, Angelica

Publication type:

Article

Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 3, p. 362, doi. 10.1002/psp4.12759

By:

Lin, Lin;
Hua, Fei;
Salinas, Cristian;
Young, Carissa;
Bussiere, Thierry;
Apgar, Joshua F.;
Burke, John M.;
Kandadi Muralidharan, Kumar;
Rajagovindan, Rajasimhan;
Nestorov, Ivan

Publication type:

Article

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer's disease.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 1, p. 7, doi. 10.1002/psp4.12728

By:

Kandadi Muralidharan, Kumar;
Tong, Xiao;
Kowalski, Kenneth G.;
Rajagovindan, Raj;
Lin, Lin;
Budd Haberlain, Samantha;
Nestorov, Ivan

Publication type:

Article

Is Aducanumab for LMICs? Promises and Challenges.

Published in:

Brain Sciences (2076-3425), 2021, v. 11, n. 11, p. 1547, doi. 10.3390/brainsci11111547

By:

Gunawardena, Illangage P. C.;
Retinasamy, Thaarvena;
Shaikh, Mohd. Farooq

Publication type:

Article

Advancing Alzheimer's care: a novel therapy with lecanemab.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2023, v. 59, n. 1, p. 1, doi. 10.1186/s41983-023-00747-y

By:

Teli, Advait;
Dhande, Priti

Publication type:

Article

Aducanumab: an uprising hope with vague horizons.

Published in:

Egyptian Journal of Neurology, Psychiatry & Neurosurgery, 2023, v. 59, n. 1, p. 1, doi. 10.1186/s41983-023-00684-w

By:

Hazegh Fetratjoo, Delara;
Kargar, Alireza;
Noroozian, Maryam

Publication type:

Article

Aducanumab Combined With Focused Brain Ultrasound More Effective.

Published in:

JAMA: Journal of the American Medical Association, 2024, v. 331, n. 6, p. 466, doi. 10.1001/jama.2023.27970

By:

Harris, Emily

Publication type:

Article

ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides.

Published in:

Interdisciplinary Sciences: Computational Life Sciences, 2025, v. 17, n. 1, p. 140, doi. 10.1007/s12539-024-00664-5

By:

Su, Yuhong;
Zeng, Xincheng;
Zhang, Lingfeng;
Bian, Yanlin;
Wang, Yangjing;
Ma, Buyong

Publication type:

Article

Monoclonal antibody therapy in Alzheimer's disease: an overview and vision.

Published in:

Brain Network & Modulation (BNM), 2024, v. 3, n. 2, p. 43, doi. 10.4103/BNM.BNM_14_23

By:

Bentley, Jonathan H.;
Bishop, Lindsey E.;
Broussard, John I.

Publication type:

Article

Donanemab: Not two without a third.

Published in:

Advances in Clinical & Experimental Medicine, 2023, v. 32, n. 10, p. 1085, doi. 10.17219/acem/172673

By:

Kurkinen, Markku

Publication type:

Article

Amyloid‐beta (Aβ)‐targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab.

Published in:

Clinical & Translational Medicine, 2024, v. 14, n. 1, p. 1, doi. 10.1002/ctm2.1559

By:

Xiao, Bin;
Tan, Eng‐King

Publication type:

Article

Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers.

Published in:

PharmacoEconomics, 2022, v. 40, n. 7, p. 647, doi. 10.1007/s40273-022-01150-w

By:

Hlávka, Jakub P.;
Lavelle, Tara A.;
Neumann, Peter J.;
Lin, Pei-Jung

Publication type:

Article

Assessments of the Value of New Interventions Should Include Health Equity Impact.

Published in:

PharmacoEconomics, 2022, v. 40, n. 5, p. 489, doi. 10.1007/s40273-022-01131-z

By:

Jansen, Jeroen P.;
Trikalinos, Thomas A.;
Phillips, Kathryn A.

Publication type:

Article

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease.

Published in:

Aging & Disease, 2021, v. 12, n. 8, p. 1964, doi. 10.14336/AD.2021.0719

By:

Abyadeh, Morteza;
Gupta, Vivek;
Gupta, Veer;
Chitranshi, Nitin;
Yunqi Wu;
Amirkhani, Ardeshir;
Meyfour, Anna;
Sheriff, Samran;
Ting Shen;
Dhiman, Kunal;
Salekdeh, Ghasem H.;
Haynes, Paul A.;
Graham, Stuart L.;
Mirzaei, Mehdi

Publication type:

Article

Synaptogenic effect of APP-Swedish mutation in familial Alzheimer's disease.

Published in:

Science Translational Medicine, 2022, v. 14, n. 667, p. 1, doi. 10.1126/scitranslmed.abn9380

By:

Zhou, Bo;
Lu, Jacqueline G.;
Siddu, Alberto;
Wernig, Marius;
Südhof, Thomas C.

Publication type:

Article

Oligomannate and Aducanumab: Novel Drugs for Alzheimer Disease.

Published in:

Ibnosina Journal of Medicine & Biomedical Sciences, 2020, v. 12, n. 4, p. 327, doi. 10.4103/ijmbs.ijmbs_114_20

By:

Rissardo, Jamir Pitton;
Caprara, Ana Letícia Fornari

Publication type:

Article

Oligomannate and Aducanumab: Novel Drugs for Alzheimer Disease.

Published in:

Ibnosina Journal of Medicine & Biomedical Sciences, 2020, v. 12, n. 4, p. 327, doi. 10.4103/ijmbs.ijmbs_114_20

By:

Rissardo, Jamir Pitton;
Fornari Caprara, Ana Letícia

Publication type:

Article

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.

Published in:

Journal of Neuroscience, 2016, v. 36, n. 50, p. 12549, doi. 10.1523/JNEUROSCI.2080-16.2016

By:

Kastanenka, Ksenia V.;
Bussiere, Thierry;
Shakerdge, Naomi;
Fang Qian;
Weinreb, Paul H.;
Rhodes, Ken;
Bacskai, Brian J.

Publication type:

Article

Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease.

Published in:

Annals of Neurology, 2023, v. 93, n. 5, p. 877, doi. 10.1002/ana.26643

By:

Musiek, Erik S.;
McDade, Eric;
Holtzman, David M.

Publication type:

Article

Reply to A Letter Concerning "Aducanumab: What About the Patient?".

Published in:: Annals of Neurology, 2022, v. 91, n. 5, p. 733, doi. 10.1002/ana.26344
Publication type:: Article

A Letter Concerning "Aducanumab: What about the Patient?".

Published in:: Annals of Neurology, 2022, v. 91, n. 5, p. 732, doi. 10.1002/ana.26333
Publication type:: Article

Reply to "Letter Concerning Moghavem, Henderson, and Greicius Article".

Published in:

Annals of Neurology, 2021, v. 90, n. 6, p. 1006, doi. 10.1002/ana.26255

By:

Moghavem, Nuriel;
Henderson, Victor W.;
Greicius, Michael D.

Publication type:

Article

Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.

Published in:: Annals of Neurology, 2021, v. 90, n. 6, p. 1004, doi. 10.1002/ana.26254
Publication type:: Article

Reply to "Thinking beyond Aducanumab Controversy".

Published in:: Annals of Neurology, 2021, v. 90, n. 6, p. 1004, doi. 10.1002/ana.26253
Publication type:: Article

Thinking beyond the Aducanumab Controversy.

Published in:: Annals of Neurology, 2021, v. 90, n. 6, p. 1003, doi. 10.1002/ana.26252
Publication type:: Article

Aducanumab: What about the Patient?

Published in:: Annals of Neurology, 2021, v. 90, n. 3, p. 334, doi. 10.1002/ana.26181
Publication type:: Article

Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.

Published in:

Annals of Neurology, 2021, v. 90, n. 3, p. 331, doi. 10.1002/ana.26167

By:

Moghavem, Nuriel;
Henderson, Victor W.;
Greicius, Michael D.

Publication type:

Article

Anti-amyloid agents for treating incipient Alzheimer's disease: a new hope?

Published in:

2022

By:

Loureiro, Julia C.;
Silva, Luiz Fernando A. L.;
Pais, Marcos V.;
Forlenza, Orestes V.

Publication type:

Editorial

New and emerging drug therapies for Alzheimer disease.

Published in:

Australian Prescriber, 2024, v. 47, n. 3, p. 75, doi. 10.18773/austprescr.2024.021

By:

Waite, Louise M.

Publication type:

Article

Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.

Published in:

2023

By:

Muralidharan, Kumar Kandadi;
Kowalski, Kenneth G.;
Tong, Xiao;
Haeberlein, Samantha Budd;
Rajagovindan, Rajasimhan;
Nestoro, Ivan

Publication type:

Correction Notice

Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.

Published in:

Journal of Pharmacokinetics & Pharmacodynamics, 2023, v. 50, n. 1, p. 45, doi. 10.1007/s10928-022-09839-3

By:

Muralidharan, Kumar Kandadi;
Kowalski, Kenneth G.;
Tong, Xiao;
Haeberlein, Samantha Budd;
Rajagovindan, Rajasimhan;
Nestorov, Ivan

Publication type:

Article

Application of <sup>89</sup>Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 5, p. 1306, doi. 10.1007/s00259-023-06109-3

By:

Stergiou, N.;
Wuensche, T. E.;
Schreurs, M.;
Mes, I.;
Verlaan, M.;
Kooijman, E. J. M.;
Windhorst, A. D.;
Helboe, L.;
Vergo, S.;
Christensen, S.;
Asuni, A. A.;
Jensen, A.;
Van Dongen, G. A. M. S.;
Bang-Andersen, B.;
Vugts, D. J.;
Beaino, W.

Publication type:

Article

Quantification of amyloid PET for future clinical use: a state-of-the-art review.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 10, p. 3508, doi. 10.1007/s00259-022-05784-y

By:

Pemberton, Hugh G.;
Collij, Lyduine E.;
Heeman, Fiona;
Bollack, Ariane;
Shekari, Mahnaz;
Salvadó, Gemma;
Alves, Isadora Lopes;
Garcia, David Vallez;
Battle, Mark;
Buckley, Christopher;
Stephens, Andrew W.;
Bullich, Santiago;
Garibotto, Valentina;
Barkhof, Frederik;
Gispert, Juan Domingo;
Farrar, Gill

Publication type:

Article

Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease.

Published in:

Neurology & Therapy, 2023, v. 12, n. 3, p. 995, doi. 10.1007/s40120-023-00466-9

By:

Saposnik, Gustavo;
Sánchez-Benavidez, Gonzalo;
García-Arcelay, Elena;
Franco-Macías, Emilio;
Bensi, Catalina;
Carmelingo, Sebastián;
Allegri, Ricardo F.;
Pérez-Martínez, David A.;
Maurino, Jorge

Publication type:

Article

Aducanumab, an investigational drug for AZ, submitted to FDA for priority review.

Published in:: Rhode Island Medical Journal, 2020, v. 103, n. 6, p. 96
Publication type:: Article

Biogen seeking FDA review in early 2020 for Aducanumab to treat early AD.

Published in:: Rhode Island Medical Journal, 2019, v. 102, n. 9, p. 56
Publication type:: Article

U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013-2018.

Published in:

2021

By:

Janiaud, Perrine;
Irony, Telba;
Russek-Cohen, Estelle;
Goodman, Steven N.

Publication type:

journal article

The Problem of Aducanumab for the Treatment of Alzheimer Disease.

Published in:

2021

By:

Alexander, G. Caleb;
Karlawish, Jason

Publication type:

Editorial

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.

Published in:

Drug Discoveries & Therapeutics, 2023, v. 17, n. 6, p. 440, doi. 10.5582/ddt.2023.01215

By:

Daoran Lu;
Fangzhou Dou;
Jianjun Gao

Publication type:

Article

Aducanumab: The first targeted Alzheimer's therapy.

Published in:

Drug Discoveries & Therapeutics, 2021, v. 15, n. 3, p. 166, doi. 10.5582/ddt.2021.01061

By:

Pan Yang;
Fusheng Sun

Publication type:

Article

Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets.

Published in:

BioScience Trends, 2024, v. 18, n. 1, p. 49, doi. 10.5582/bst.2023.01288

By:

Xiaolei Gu;
Long Qi;
Qing Qi;
Jing Zhou;
Song Chen;
Ling Wang

Publication type:

Article